• Cancer is the leading cause of death in Australia, with about 1 in 2 Australian men and 1 in 3 Australian women will be diagnosed with cancer in their life.
  • Clinical trials play an essential role in discovering new and more effective treatments for cancer.
  • Outstanding research-based health care is provided to all participants involved in clinical trials and we offer comprehensive and integrated evidence-based treatment options.
 
  • Gynaecological Cancers
  • Breast Cancer
  • Pancreatic/Upper Gastrointestinal Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Brain Cancer
  • Melanoma
 
Head of Department, Cancer Services
Dr Andrew Dean

Head of Palliative Care Services
Dr Derek Eng

Medical Registrar
Dr Meabh McNulty, Dr Dom Higgs

Project Manager – Clinical Trials Development
Dr Jo Youd

Research Data Scientist
Andrew Mews

Please see Oncology Clinical Trial Unit for all other key staff
 
Das, A., Dean, A., Clay T. Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma. (2019) BMJ Case Reports CP 12:e228363
http://dx.doi.org/10.1136/bcr-2018-2283633

Travers, N., Cronin, E., Marinova, M., Smith, P., Dean, A.P. Anaplastic thyroid cancer: A report of six consecutive cases treated successfully with nab-paclitaxel (2019) Journal of Clinical Oncology 2019 37:15_suppl, e17586-e17586

Dean, A.P., Das, A., McNulty, M., Higgs, D. Gemcitabine and nab-paclitaxel retreatment as a third-line therapy following second-line FOLFIRINOX for advanced pancreatic adenocarcinoma. Journal of Clinical Oncology 37, 2019 (suppl; abstract e15794)
https://doi:10.1200/JCO.2019.37.15
 
Shaughnessy, E., Armstrong, K., Rogers-Seeley, M., Das, A., Higgs, D., Dean, A.P. Pneumocystis jiroveci pneumonia during first and second-line chemotherapy for solid tumours. Journal of Clinical Oncology 2019 37:15_suppl, e18330-e18330
https://10.1200/JCO.2019.37.15

Rogers, P., Jones, C., Dean, A
. A rare skin condition masquerading as a serious wound infection J Surg Case Rep. 2018 Nov; 2018(11): rjy299.
https://doi:10.1093/jscr/rjy299

McNulty, M., Dean, A., Das, A., Gordon, M. Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first-line gemcitabine for advanced pancreatic adenocarcinoma. Annals of Oncology 29, no. suppl_5 (2018): mdy151-146.
https://doi.org/10.1093/annonc/mdy151.146

Hardcastle, S. J., Kane, R., Chivers, P., Hince, D., Dean, A., Higgs, D., Cohen, P.A. Knowledge, attitudes, and practice of oncologists and oncology health care providers in promoting physical activity to cancer survivors: an international survey. Support Care Cancer. 2018 Nov; 26(11) :3711-3719.
https://doi:10.1007/s00520-018-4230-1

Dean, AP., Higgs, D., Robins, P., Stobie, P., Craven, P., Daly, C., Carija, S. Use of FDG PET scanning to evaluate 5-FU myocardial toxicity as a global metabolic effect rather than vascular spasm. Journal of Clinical Oncology 36, no. 4_suppl (February 1 2018) 792-792
https://doi:10.1200/JCO.2018.36.4_suppl.792

Aghajanian, C., Coleman, R.L, Oza, A.M., Lorusso, D., Oaknin, A., Dean, A.P., Colombo, N. et al. Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study. Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 5537-5537
https://doi:10.1200/JCO.2018.36.15_suppl.5537

You may be interested in